Perspectives on shorter durations of anti-HER2 therapy in early-stage HER2-positive breast cancer: a patient survey.

[1]  M. Savard,et al.  Shorter Durations of Anti-HER2 Therapy for Patients with Early-Stage, HER2-Positive Breast Cancer: The Physician Perspective , 2023, Current oncology.

[2]  M. Piccart,et al.  DECRESCENDO: de-escalating chemotherapy in HER2-positive, estrogen receptor-negative, node-negative early breast cancer. , 2023, Future oncology.

[3]  N. Keating,et al.  Breast cancer knowledge and understanding treatment rationales among diverse breast cancer survivors , 2022, Breast Cancer Research and Treatment.

[4]  C. Omarini,et al.  T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysis , 2022, BMC cancer.

[5]  J. Abraham,et al.  LBA11 Individual patient data meta-analysis of 5 non-inferiority RCTs of reduced duration single agent adjuvant trastuzumab in the treatment of HER2 positive early breast cancer , 2021, Annals of Oncology.

[6]  E. de Azambuja,et al.  Cardiotoxicity of trastuzumab given for 12 months compared to shorter treatment periods: a systematic review and meta-analysis of six clinical trials , 2020, ESMO Open.

[7]  D. Yee,et al.  I-SPY 2: a Neoadjuvant Adaptive Clinical Trial Designed to Improve Outcomes in High-Risk Breast Cancer , 2019, Current Breast Cancer Reports.

[8]  F. Cardoso,et al.  Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  B. Hutton,et al.  Creating a pragmatic trials program for breast cancer patients: Rethinking Clinical Trials (REaCT) , 2019, Breast Cancer Research and Treatment.

[10]  N. Biglia,et al.  Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study‡ , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  A. Musolino,et al.  9 weeks versus 1 year adjuvant trastuzumab for HER2+ early breast cancer: Subgroup analysis of the ShortHER trial allows to identify patients for whom a shorter trastuzumab administration may have a favourable risk/benefit ratio. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  B. Gyawali,et al.  Optimal duration of adjuvant trastuzumab in treatment of early breast cancer: a meta-analysis of randomized controlled trials , 2018, Breast Cancer Research and Treatment.

[13]  P. Neven,et al.  Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: The SOLD Randomized Clinical Trial , 2018, JAMA oncology.

[14]  G. Eysenbach.  Improving the Quality of Web Surveys: The Checklist for Reporting Results of Internet E-Surveys (CHERRIES) , 2004, Journal of medical Internet research.